

IN THE CLAIMS

Please amend the claims as follows:

*Full  
B7C*

1. (Amended) A method for preventing constrictive remodeling comprising a controlled delivery, by release from an intraluminal medical device, of an anti-proliferative/anti-inflammatory compound in therapeutic dosage amounts, the compound substantially reducing in-lesion lumen loss both proximate and distal to the intraluminal medical device.

*Sub.D1 >  
b1*

2. (Amended) The method for preventing constrictive remodeling according to Claim 1, further includes utilizing the compound to block a proliferation of fibroblasts in a vascular wall in response to injury, thereby reducing a formation of vascular scar tissue.

3. (Amended) The method for preventing constrictive remodeling according to Claim 2, wherein the compound comprises rapamycin.

4. (Amended) The method for preventing constrictive remodeling according to Claim 2, wherein the compound comprises analogs and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses pharmacologic properties equivalent to rapamycin.

5. (Amended) The method for preventing constrictive remodeling according to Claim 1, further includes utilizing the

Sub.D1 > B1 compound to affect a translation of certain proteins involved in a collagen formation or metabolism.

6. (Amended) The method for preventing constrictive remodeling according to Claim 5, wherein the compound comprises rapamycin.

7. (Amended) The method for preventing constrictive remodeling according to Claim 5, wherein the compound comprises analogs and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses pharmacologic properties equivalent to rapamycin.

8. (Amended) A drug delivery device comprising:

an intraluminal medical device; and

a therapeutic dosage of an anti-proliferative/anti-inflammatory agent releasably affixed to the intraluminal medical device for treatment of constrictive vascular remodeling, the agent substantially reducing in-lesion lumen loss both proximal and distal to the intraluminal medical device.

Sub.D1 > 9. (Amended) The drug delivery device according to Claim 8, wherein the agent blocks a proliferation of fibroblasts in a vascular wall in response to injury, thereby reducing a formation of vascular scar tissue.

~~Sub.D1> 11. (Amended) The drug delivery device according to Claim 9, wherein the agent comprises analogs and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses pharmacologic properties equivalent to rapamycin.~~

~~12. (Amended) The drug delivery device according to Claim 8, wherein the agent affects the translation of certain proteins involved in collagen formation or metabolism.~~

~~Sub.D1> 14. (Amended) The drug delivery device according to Claim 12, wherein the agent comprises analogs and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses pharmacologic properties equivalent to rapamycin.~~

~~15. (Amended) The drug delivery device according to Claim 8, wherein the intraluminal medical device comprises a stent.~~

#### REMARKS

In response to the Office Action mailed October 2, 2002, Applicants amend their application and request reconsideration in view of the amendment and the following remarks in this Reply/Amendment. Claims 1-9, 11, 12, 14 and 15 were amended, no claims have been added or cancelled so that claims 1-16 remain pending. No new matter has been introduced.